The Johnson administration hasn't drafted a specific ordinance, but the breadth and cost of the local regulations suggested ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

Like VK2809, VK0214 is also an orally available small molecule that is selected for the beta isoform of the thyroid hormone receptor. X-ALD is a rare and debilitating metabolic disorder that is ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

Supporters of gender-affirming care called on the University of Illinois health care system to be clearer and more ...

As a result, patients are unable to efficiently metabolize these acids, and their accumulation is believed to contribute to the onset and progression of X-ALD. Activation of the thyroid hormone ...

and the Phase 1b study of VK0214 for X-ALD. Each of these studies successfully achieved their objectives with each in our view demonstrating best-in-class data. During the year, the company ...

The Queensland government has announced a review into the evidence for stage one and two hormone therapies for children with gender dysphoria. While the review is underway, a pause will be placed ...

Children with gender dysphoria will be denied puberty blockers as a state government reviews hormone therapies for minors. The Queensland government launched the investigation after reports that ...